Lv630
2590 积分 2022-02-14 加入
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
12天前
已完结
New immune cell engagers for cancer immunotherapy
14天前
已完结
The present and future of bispecific antibodies for cancer therapy
14天前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
14天前
已完结
Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach
17天前
已完结
Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis
1个月前
已完结
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)
1个月前
已完结
Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors
1个月前
已完结
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
2个月前
已关闭
Disrupting B and T cell Collaboration in Autoimmune Disease: T cell engagers versus CAR T cell therapy?
2个月前
已完结
皖公网安备34019202002308
